Loading...
•
Jun 30, 2021
Tandem Diabetes Q2 2021 Earnings Report
Tandem Diabetes Care's Q2 2021 financial results were announced, featuring increased sales and pump shipments.
Key Takeaways
Tandem Diabetes Care reported a strong second quarter with a 58% increase in sales to $172.1 million and an 81% increase in worldwide pump shipments. The company updated its full-year sales guidance to $670 million to $685 million.
Worldwide pump shipments increased 81% to 33,817 pumps.
Sales increased 58% to $172.1 million.
Gross margin improved to 54% of sales.
Operating margin improved to 3% of sales.
Revenue by Geographic Location
Forward Guidance
The company updated its financial guidance for the year ending December 31, 2021.
Positive Outlook
- Sales are estimated to be in the range of $670 million to $685 million, representing 34% to 37% annual sales growth compared to 2020.
- International sales are projected to be approximately $160 million to $165 million, indicating 92% to 98% annual sales growth compared to 2020.
- Gross margin is estimated to be approximately 55%.
- Adjusted EBITDA is estimated to be approximately 15% of sales.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...